Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from an analysis determining the validity of the Registry to...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the latest research from its innovative oncology portfolio and pipeline of...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) for XARELTO®...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new real-world analysis of more than 700,000 U.S....
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a new late-breaking analysis (OBSERVE-4D) examining how INVOKANA®...
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced results from a Phase 2 study that were published in The Lancet...
The Janssen Pharmaceutical Companies of Johnson & Johnson today presented a post-hoc analysis from the Phase 3 SPARTAN study that showed treatment...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has entered a new worldwide collaboration with Bristol-Myers Squibb ...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new analysis showing that INVOKANA® (canagliflozin)...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new home-based clinical trial showing that a...
New studies and late-breaking analyses from the Janssen Pharmaceutical Companies of Johnson & Johnson are among the 11 company abstracts accepted for ...
New real-world findings published in The Journal of Clinical Psychiatry expand on the growing evidence that people with treatment-resistant...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance...
New data from the Janssen Pharmaceutical Companies of Johnson & Johnson will be presented at the American Society of Clinical Oncology Genitourinary...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel...
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Johnson & Johnson Innovation LLC, in...
Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA® (canagliflozin)...
Janssen Research & Development, LLC today announced additional analyses from the landmark CANVAS clinical trial program showing INVOKANA®...
New data for the immunotherapy DARZALEX® (daratumumab) and first-in-class BTK inhibitor IMBRUVICA® (ibrutinib) are among eight oral presentations...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.